Reactivation of Chagas disease in a heart transplant patient infected by sylvatic Trypanosoma cruzi discrete typing unit I

Inga, Leydi Alexandra Ceballos; Olivera, Mario Javier

doi:10.1590/0037-8682-0512-2018

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Costales et al. (2015) ( 264 ) and Inga and Oliveira (2019) ( 265 ) related the reactivation of the disease to the parasites of the TcI, as previously found in cases of reactivation by HIV co-infection ( 263 ). Cura et al.…”

Section: Immunosuppression and Reactivation Of The Chagas Diseasementioning

confidence: 58%

New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes

Silvestrini,

Alessio,

Frias

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Chagas disease, caused by Trypanosoma cruzi, remains a serious public health problem worldwide. The parasite was subdivided into six distinct genetic groups, called “discrete typing units” (DTUs), from TcI to TcVI. Several studies have indicated that the heterogeneity of T. cruzi species directly affects the diversity of clinical manifestations of Chagas disease, control, diagnosis performance, and susceptibility to treatment. Thus, this review aims to describe how T. cruzi genetic diversity influences the biology of the parasite and/or clinical parameters in humans. Regarding the geographic dispersion of T. cruzi, evident differences were observed in the distribution of DTUs in distinct areas. For example, TcII is the main DTU detected in Brazilian patients from the central and southeastern regions, where there are also registers of TcVI as a secondary T. cruzi DTU. An important aspect observed in previous studies is that the genetic variability of T. cruzi can impact parasite infectivity, reproduction, and differentiation in the vectors. It has been proposed that T. cruzi DTU influences the host immune response and affects disease progression. Genetic aspects of the parasite play an important role in determining which host tissues will be infected, thus heavily influencing Chagas disease’s pathogenesis. Several teams have investigated the correlation between T. cruzi DTU and the reactivation of Chagas disease. In agreement with these data, it is reasonable to suppose that the immunological condition of the patient, whether or not associated with the reactivation of the T. cruzi infection and the parasite strain, may have an important role in the pathogenesis of Chagas disease. In this context, understanding the genetics of T. cruzi and its biological and clinical implications will provide new knowledge that may contribute to additional strategies in the diagnosis and clinical outcome follow-up of patients with Chagas disease, in addition to the reactivation of immunocompromised patients infected with T. cruzi.

show abstract

Section: Immunosuppression and Reactivation Of The Chagas Diseasementioning

confidence: 58%

New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes

Silvestrini,

Alessio,

Frias

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…This fact made HT as a treatment for Chagas cardiomyopathy initially controversial. However, currently, especially in endemic countries, it is the most viable therapeutic option for patients with end-stage heart failure [24]. We hypothesize that, in the cases presented here, HT followed by reactivation of CD conferred an additional risk factor for the worsening of COVID-19.…”

Section: Discussionmentioning

confidence: 77%

SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report

Gozzi-Silva

Benard²,

Alberca³

et al. 2021

TropicalMed

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a pandemic. SARS-CoV-2 infection can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure. Individuals receiving a heart transplantation (HT) may be at higher risk of adverse outcomes attributable to COVID-19 due to immunosuppressives, as well as concomitant infections that may also influence the prognoses. Herein, we describe the first report of two cases of HT recipients with concomitant infections by SARS-CoV-2, Trypanosoma cruzi, and cytomegalovirus (CMV) dissemination, from the first day of hospitalization due to COVID-19 in the intensive care unit (ICU) until the death of the patients.

show abstract

Ciclosporin/mycophenolate mofetil/prednisone

2019

Reactions Weekly

View full text Add to dashboard Cite

Reactivation of Chagas disease in a heart transplant patient infected by sylvatic Trypanosoma cruzi discrete typing unit I

Cited by 4 publications

References 12 publications

New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes

New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes

SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report

Ciclosporin/mycophenolate mofetil/prednisone

Contact Info

Product

Resources

About